Vitasora Health Limited
0.01
AUD
+0.00
(-7.69%)
ISIN
AU0000392748
Return %
Stock
S&P 500
1Y
-53.85
14.20
3Y
-67.57
81.12
5Y
-82.09
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Marjan Mikel
- Full Time Employees
- 30
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 432 St Kilda Road Melbourne VIC Australia 3004
- IPO Date
- Apr 15, 2025
- Website
- respiri.co
- Similar Companies
- Business
- Vitasora Health Limited operates as a U.S.-focused connected care management company that integrates remote patient monitoring, AI-powered clinical decision support, and virtual clinic capabilities to extend patient care beyond traditional clinic settings; it targets chronic disease management across cardiovascular, diabetes, obesity, and respiratory conditions, delivering data-driven care programs to healthcare providers to improve outcomes and reduce costs. The company emphasizes value-based care, operational scalability, and partnerships with healthcare systems to broaden care capacity through multi-device monitoring, virtual clinical support, and AI-enabled insights. VHL.AX is listed on the Australian Securities Exchange and is headquartered in Melbourne, Australia, with a strategic emphasis on expanding its U.S. market footprint, including collaborations with U.S. medical groups and health systems to scale its Connected Care platform. Since its rebranding from Respiri Limited in 2025, Vitasora reinforces a shift toward comprehensive digital health services, expanding contractual arrangements, and advancing capital-raising activities to fund technology, clinical operations, and business development, aiming for profitability and cash-flow breakeven in the near term. Founding year and headquarters are identified as 1987 and Melbourne, Australia, respectively, with ongoing development of product suites comprising remote monitoring devices, AI-driven care management, home-based and chronic-care program integration, and partner-enabled care orchestration. The company’s latest major changes include a series of strategic alliances and contracts in the U.S. market, cornerstone funding rounds completed in late 2025, and expanded scope initiatives across existing clients to accelerate revenue growth and scale its Connected Care offering. Vitasora’s business model centers on providing clinicians and care teams with enhanced patient visibility, integrated data flows, and scalable care management services designed to support population health programs in the United States, backed by a corporate strategy to achieve profitability within the 2026 financial year.